International congress – Congres IPS http://congresips.com/ Wed, 28 Sep 2022 02:06:54 +0000 en-US hourly 1 https://wordpress.org/?v=5.9 https://congresips.com/wp-content/uploads/2021/10/default-120x120.png International congress – Congres IPS http://congresips.com/ 32 32 Opening in Cameroon of an international congress on endoscopic gynecological surgery https://congresips.com/opening-in-cameroon-of-an-international-congress-on-endoscopic-gynecological-surgery/ Tue, 27 Sep 2022 04:15:55 +0000 https://congresips.com/opening-in-cameroon-of-an-international-congress-on-endoscopic-gynecological-surgery/ The 2nd International Congress of the International Society of Gynecological Endoscopy (ISGE) and the African Society of Gynecological Endoscopy (AFSGE) opened Monday in Yaoundé, the capital of Cameroon. The congress aims to “improve minimally invasive gynecological surgery in an African context” and expects to be a “turning point for the future of gynecological endoscopic surgery […]]]>

spinning

The 2nd International Congress of the International Society of Gynecological Endoscopy (ISGE) and the African Society of Gynecological Endoscopy (AFSGE) opened Monday in Yaoundé, the capital of Cameroon.

The congress aims to “improve minimally invasive gynecological surgery in an African context” and expects to be a “turning point for the future of gynecological endoscopic surgery in Africa” in terms of development and expansion. The congress will end on Friday.

Gynecological endoscopy is a surgical discipline that uses specially designed optical instruments to help diagnose gynecological diseases and conditions, such as certain infertility problems and minor vaginal bleeding.

Jean Marie Kasia, President of AFSGE, said that world-renowned surgeons in this field will be present at the congress, which will also seek revolutionary and innovative approaches for the management of endoscopic procedures.

“During the conference, practitioners will improve their surgical skills. This provides an opportunity for innovation, collaboration and cooperation in research on endoscopic surgery and human reproduction,” Kasia said. Final article

Send your news to newsghana101@gmail.com
Follow Ghana News on Google New

Aviator


Source link

]]>
Poland will host the 6th International Congress of Turkology https://congresips.com/poland-will-host-the-6th-international-congress-of-turkology/ Fri, 16 Sep 2022 15:09:00 +0000 https://congresips.com/poland-will-host-the-6th-international-congress-of-turkology/ Baku, September 16, AZERTAC From September 19 to 21, the 6th International Turkology Congress entitled “Turkish World Studies – Multidisciplinary Perspectives” will be held in Poland, organized by the University of Warsaw. The main partners of the Congress are the International Turkish Culture and Heritage Foundation, the embassies of Azerbaijan, Turkey, Kazakhstan and Uzbekistan in […]]]>

Baku, September 16, AZERTAC

From September 19 to 21, the 6th International Turkology Congress entitled “Turkish World Studies – Multidisciplinary Perspectives” will be held in Poland, organized by the University of Warsaw. The main partners of the Congress are the International Turkish Culture and Heritage Foundation, the embassies of Azerbaijan, Turkey, Kazakhstan and Uzbekistan in Poland, as well as the Yunus Emre Institute and the Karaite Heritage Foundation. President of the International Turkish Culture and Heritage Foundation Gunay Afandiyeva will attend the Congress as guest of honour.

The Congress should hold discussions on the history, politics, economy, art, language and literature of the Turkic peoples, including the geographical areas inhabited by the Turks today and in the past, as well as modern studies and research carried out in this field.

Within the framework of the Congress, it is planned to organize a round table devoted to Shusha, the cultural capital of Azerbaijan and the Turkish world, as well as an exhibition based on rare photographs reflecting the history, social life, political and cultural program of Shusha, a performance by a mugham trio and a presentation of samples of the national cuisine.

Within the framework of the Congress, the presentation of a book by Guler Abdullabayova, representative of the Institute of Literature named after Nizami Ganjavi of ANAS, telling about the literary ties between Azerbaijan and Poland in the 19th century, will be carried out .

© Content on this site must be hyperlinked when used.


Source link

]]>
The 66th EUHA International Congress starts on October 12 https://congresips.com/the-66th-euha-international-congress-starts-on-october-12/ Fri, 16 Sep 2022 13:32:08 +0000 https://congresips.com/the-66th-euha-international-congress-starts-on-october-12/ The 66th International Congress of Hearing Aid Professionals of the European Union of Hearing Aid Professionals (EUHA) and accompanying industry exhibition, starting October 12, 2022, will provide insight into innovations in the field of hearing, according to an announcement from the EUHA. More than 25 expert talks, five tutorials and four prospective Future Friday talks […]]]>

The 66th International Congress of Hearing Aid Professionals of the European Union of Hearing Aid Professionals (EUHA) and accompanying industry exhibition, starting October 12, 2022, will provide insight into innovations in the field of hearing, according to an announcement from the EUHA.

More than 25 expert talks, five tutorials and four prospective Future Friday talks will be offered to participants. In addition, the 66th EUHA International Congress will inaugurate the EUHA Scientific Symposium from October 12, Wednesday morning. Approximately 120 exhibitors, from 17 countries, including 17 new exhibitors, will showcase their latest technologies in 14,500 square meters (47,572 feet) of reserved exhibit space in Hall 6, along with a special program on Future Friday. The meeting of the Congress on Thursday evening will be an opportunity to celebrate and discuss.

EUHA 2022 Showroom The showroom is located in the press center in rooms 13/14, and will be open to anyone interested during the following times: Thursday from 9:00 a.m. to 5:00 p.m. and Friday from 9:00 a.m. to 1:00 p.m. The 2022 flagship products will be presented there. Each on a separate pedestal! All Congress delegates are invited to take advantage of a relaxed atmosphere to get a glimpse of innovations in the field of hearing.

Online ticketing Tickets can only be purchased online – the Ticket Shop is open 24/7, even during the Congress period. In line with the current trend, there will be no ticket office on site. Take a look and quickly secure your ticket at www.euha.org. For the first time, pupils, apprentices and students can purchase a discounted ticket for the third day of the Congress for 40 euros (USD $40). It’s a great opportunity to learn about the technologies being showcased by hearing system manufacturers and other service providers at the show, as well as attend exciting Future Friday talks starting at 2:00 p.m.

Wireless

The free “MESSEfreewifi” is available on the premises of the Deutsche Messe Hannover.

Congress schedule at a glance:

Opening of the Congress with the Scientific Symposium (Room 3):

Warning: NEW TIME!

Wed 12 Oct 2022: 10am-12pm

Showroom (rooms 13/14)

Thursday, October 13, 2022: 9 a.m. to 5 p.m.

Friday, October 14, 2022: 9 a.m. to 1 p.m.

Expert conferences (Room 3):

Wednesday, October 12, 2022: 1 p.m. to 4 p.m.

Thursday, October 13, 2022: 9:30 a.m. to 4:30 p.m.

Friday, October 14, 2022: 9:30 a.m. to 1:00 p.m.

Upcoming Friday Lectures (Room 3):

Friday, October 14, 2022: 2 p.m.-4:15 p.m.

Tutorials (Rooms 13/14)

Thursday, October 13, 2022: 9:30 a.m. to 5:00 p.m.: T1-T4

Friday, October 14, 2022: 9:30 a.m. to 11:00 a.m.: T5

Congress Gather (Convention Center, Foyer)

Thursday, October 13, 2022: 7 a.m. – approx. 11:30 p.m.

Source: EUHA


Source link

]]>
Amprion exhibits at the MDS International Congress on Parkinson’s Disease and Movement Disorders in Madrid and presents scientific information on the SYNTap® test at Prion2022 https://congresips.com/amprion-exhibits-at-the-mds-international-congress-on-parkinsons-disease-and-movement-disorders-in-madrid-and-presents-scientific-information-on-the-syntap-test-at-prion2022/ Thu, 15 Sep 2022 22:00:00 +0000 https://congresips.com/amprion-exhibits-at-the-mds-international-congress-on-parkinsons-disease-and-movement-disorders-in-madrid-and-presents-scientific-information-on-the-syntap-test-at-prion2022/ Amprion, leader in the diagnosis of neurodegenerative diseases, invites researchers and practitioners to the international MDS congress to Madrid to visit Amprion at booth #212 and discuss how the SYNTap® Biomarker Test addresses the unmet medical need for a validated clinical test to diagnose Parkinson’s disease (PD) and differentiate PD from Parkinson’s disease atypical at […]]]>

Amprion, leader in the diagnosis of neurodegenerative diseases, invites researchers and practitioners to the international MDS congress to Madrid to visit Amprion at booth #212 and discuss how the SYNTap® Biomarker Test addresses the unmet medical need for a validated clinical test to diagnose Parkinson’s disease (PD) and differentiate PD from Parkinson’s disease atypical at an early stage. Amprion will host a Meet the Expert session with neurologist Brit Mollenhauer, MD, where attendees can discuss the science behind how the SYNTap test works in a clinical setting. The session will take place Friday September 15 of 10 a.m. to 12 p.m. at booth #212. In addition to exposure to MDS, Amprion Chief Scientific Officer Claudio SotoPh.D., will speak at the Prion2022 International Conference, September 13-16 in Goettingen, Germany.

SAN FRANCISCO, September 15, 2022 /PRNewswire-PRWeb/ — Amprion, a leader in the diagnosis of neurodegenerative diseases, invites researchers and practitioners attending MDS to visit Amprion at booth #212. We look forward to discussing how the biomarkers SYNTap® addresses the unmet medical need for a validated clinical test to diagnose Parkinson’s disease (PD) and differentiate PD from atypical Parkinson’s disease at an early stage. Accurate and early diagnosis can accelerate personalized treatments and therapeutic innovations.

The urgent medical need for accurate and early diagnosis of neurodegenerative diseases increases as the world’s population ages. For every thousand people, 1 to 2 people are affected by Parkinson’s disease. The prevalence of PD increases with age, affecting 1% of the population aged 60 and over. Worldwide, about 10 million people could have PD.

Amprion’s SYNTap biomarker test helps physicians diagnose and differentiate complex and often confusing neurodegenerative diseases, including Parkinson’s disease, Lewy body variant of Alzheimer’s disease, Lewy body dementia, mild cognitive impairment with Lewy bodies and multiple system atrophy. The company’s proprietary detection technology, Seed Amplification Assay (SAA), accurately detects misfolded α-synuclein aggregates, a crucial biomarker associated with these devastating conditions.

“The SYNTap test fills the void for a highly sensitive and specific clinical diagnostic tool,” said Amprion Chief Scientific Officer Claudio SotoPh.D., who will speak at Prion2022, September 13-16 in Goettingen, Germany. According Russ Lebovitz, MD/Ph.D, CEO of Amprion, “Sure diagnosis enables the optimization of personalized treatment and disease management strategies for people with Parkinson’s disease and movement disorders.” Dr. Lebovitz will attend the MDS, International Congress on Parkinson’s Disease and Movement Disorders in Madrid, September 15-18.

Amprion will host a Meet the Expert session where attendees can discuss the science behind how the SYNTap assay performs in a clinical setting.

MEET THE EXPERT – Friday September 1510 a.m. to 12 p.m. – Booth #212

Neurologist Brit MollenhauerMD, specializes in Parkinson’s disease and movement disorders and directs translational research at the Paracelsus-Elena Klinik (PEKK) in Germany. It has developed a study center for clinical trials and translational research and works closely with the Michael J. Fox Foundation for Parkinson’s Disease Research.

“The AAS developed by Amprion offers highly accurate detection of misfolded synuclein in cerebrospinal fluid (CSF), which can serve as a diagnostic for patients suspected of having Parkinson’s disease, Lewy body dementia and multiple system atrophy, all of which are disorders of synuclein aggregation.”

Dr. Mollenhauer will discuss the value of Amprion’s SYNTap test in the early identification of synucleinopathy based on his studies: “We have shown that in one of our cohorts of patients with REM sleep behavior disorder (RBD), a prodromal condition of synuclein aggregation disorders, the SYNTap test can detect misfolded synuclein at least a decade before a clinical diagnosis of synuclein aggregation disorders can be made.”

We look forward to meeting you at MDS Booth #212.
Download the SYNTap test data sheet.

ABOUT AMPRION
A leader in the science of prion detection™, Amprion innovates biomarker testing for brain disease. Our SYNTap® biomarker test helps diagnose Parkinson’s disease, Lewy body dementia and Lewy body variant Alzheimer’s disease. Amprion has received FDA Breakthrough Device Designation for detecting misfolded synuclein in CSF. We strive to accelerate personalized medicine for neurodegenerative diseases through molecular testing.

Media Contact

Jordan LeeAmprion, 727-447-4992 104, jordan.lee@theprgroup.com

SOURCEAmprion


Source link

]]>
The Parkinson Foundation presents six studies at the MDS International Congress 2022 | Company https://congresips.com/the-parkinson-foundation-presents-six-studies-at-the-mds-international-congress-2022-company/ Thu, 15 Sep 2022 15:04:23 +0000 https://congresips.com/the-parkinson-foundation-presents-six-studies-at-the-mds-international-congress-2022-company/ MIAMI and NEW YORK, Sept. 15, 2022 /PRNewswire/ — The Parkinson’s Foundation will present six scientific posters highlighting research, care and education at the 2022 International Congress on Parkinson’s Disease and Movement Disorders® hosted by the International Parkinson and Movement Disorders Society. Running until September 18, the event brings together thousands of movement disorder specialists […]]]>

MIAMI and NEW YORK, Sept. 15, 2022 /PRNewswire/ — The Parkinson’s Foundation will present six scientific posters highlighting research, care and education at the 2022 International Congress on Parkinson’s Disease and Movement Disorders® hosted by the International Parkinson and Movement Disorders Society. Running until September 18, the event brings together thousands of movement disorder specialists – including top neurologists and Parkinson’s disease (PD) researchers – to share insights that can move the field forward. Selected as a poster tour accolade, the Foundation’s PD GENEration Genetic Registry study will be featured multiple times, including a guest plenary presentation by Principal Investigator, Roy Alcalay, MD, MS.

“The recognition of PD GENEration at an international forum is a testament to the impact this study has already had in the field and represents our commitment to bringing improvements to Parkinson’s disease care and research,” said the Associate Vice President of Clinical Research Anna Naito, PhD, of the Parkinson Foundation. “We are confident that PD GENEration’s contributions to the global research community will bring us closer to scientific breakthroughs. Through PD GENEration, we have developed international collaborations with experts from across the field, enabling us to accelerate the field of research and treatment globally.

Parkinson’s Foundation poster presentations will include:

Curation of Parkinson’s disease genes and gene variants by an authoritative panel of experts

With advances in the field of Parkinson’s disease toward precision medicine, the Foundation has established an expert panel for PD genetics under ClinGen – an FDA-recognized global resource that uses criteria at the scale to determine gene-disease relationships. The members of the PD Gene Curation Expert Panel (PD GCEP) bring together 58 experts from several countries representing geneticists, Parkinson’s clinicians, biochemists, genetic counselors and pharmaceutical companies. The PD GCEP aims to inform the FDA and pharmaceutical companies on the prioritization of key disease-related genes.

Closing the Gap: Increasing Access to Genetic Testing and Counseling for Hispanics through Parkinson’s Research

This poster describes the efforts of the PD GENEration Genetic Registry Study and the GEN-EP Latino Study to reach Hispanic populations in the United States, Puerto Rico, and the Dominican Republic. Preliminary results include a total of 22 Hispanic participants identified as carriers of a well-known pathogenic/probably pathogenic variant of PD, representing 14.5% of all individuals tested. Increasing the diversity of genetic data from diverse populations will help accelerate understanding of the causes and many symptoms associated with PD.

PD GENEration clinical phase: genetic diagnostic yield and clinical characteristics

This study aims to assess the prevalence of genetic forms of PD in North America using PD GENEration. Among the North American PD GENEration cohort, 14.8% of participants carried a genetic variant linked to PD. Widespread genetic testing in North America will help identify previously unsuspected individuals with major PD gene variants and ultimately qualify more people for enrollment in precision medicine clinical trials for PM.

Implementation of team-based outpatient palliative care at Parkinson Foundation Centers of Excellence (COEs): study design

Despite accumulating evidence on the benefits of integrated palliative care (PC) approaches for people with neurological conditions and their families, there are few models on how to implement and spread this model of care. The core intervention is based on a successful team-based CP model developed at three Parkinson Foundation Centers of Excellence in the United States and validated in a multi-site randomized controlled trial. This poster describes the study design and early lessons of an implementation project to make integrated CP a new standard of care at all 33 Centers of Excellence in the United States.

Patient Advisory Committees: A Model for Patient Involvement in Comparative Effectiveness Research in Parkinson’s Disease

To address the lack of comparative effectiveness research (CER) in PD and the need to begin building infrastructure to fill this gap, this pilot project aimed to create a replicable and sustainable model of patient engagement in PD. PD CER in academic research centers through Patient Advice Cards (PAB). This pilot project offers a patient engagement model in academic PD research centers that can facilitate the involvement of people with PD from the community at different stages of the research process, such as when setting priorities. research, protocol design and considerations.

Screening and Treatment for Depression in Parkinson’s Disease in Movement Disorders Centers: A Quality Improvement Initiative

A significant proportion of people with PD who report depressed mood do not receive mental health services or treatment. This study aims to assess the feasibility of routine screening for depression using a 15-question survey of people with PD at six centers of excellence and to identify barriers within the specialist setting for depression. movement. Systematic screening for depression will help improve quality of care and quality of life by educating both clinicians and people with PD.

To view and learn more about the Parkinson Foundation research findings presented at the 2022 MDS International Congress, visit Parkinson.org/Blog. To learn more about the Foundation’s commitment to research, visit Parkinson.org/Research.

About the Parkinson Foundation

The Parkinson Foundation improves the lives of people with Parkinson’s disease by improving care and advancing the search for a cure. In everything we do, we draw on the energy, experience and passion of our global Parkinson’s community. Since 1957, the Parkinson Foundation has invested more than $400 million in research and clinical care for Parkinson’s disease. Join us on Parkinson.org, Facebook, TwitterInstagram or call (800) 4PD-INFO (473-4636).

About Parkinson’s disease

Affecting approximately one million Americans and 10 million worldwide, Parkinson’s disease is the second most common neurodegenerative disease after Alzheimer’s disease and the 14th leading cause of death in the United States. It is associated with progressive loss of motor control (eg, tremors or tremors at rest and lack of facial expression), as well as non-motor symptoms (eg, depression and anxiety). Parkinson’s disease is incurable and 60,000 new cases are diagnosed each year in the United States alone.

MEDIA CONTACT:

Marissa Cruz

Parkinson Foundation

mcruz@parkinson.org

305-537-9926

parkinson.org

View original content to download multimedia: https://www.prnewswire.com/news-releases/parkinsons-foundation-presents-six-studies-at-mds-international-congress-2022-301624737.html

SOURCE Parkinson Foundation



Source link

]]>
The Parkinson Foundation presents six studies at the 2022 MDS International Congress https://congresips.com/the-parkinson-foundation-presents-six-studies-at-the-2022-mds-international-congress/ Thu, 15 Sep 2022 12:55:00 +0000 https://congresips.com/the-parkinson-foundation-presents-six-studies-at-the-2022-mds-international-congress/ MIAMI and NEW YORK, September 15, 2022 /PRNewswire/ — The Parkinson’s Foundation to Present Six Scientific Posters Highlighting Research, Care and Education at the 2022 International Congress on Parkinson’s Disease and Movement Disorders® hosted by the International Parkinson and Movement Disorders Society . Rolling through September 18, the event brings together thousands of movement disorder […]]]>

MIAMI and NEW YORK, September 15, 2022 /PRNewswire/ — The Parkinson’s Foundation to Present Six Scientific Posters Highlighting Research, Care and Education at the 2022 International Congress on Parkinson’s Disease and Movement Disorders® hosted by the International Parkinson and Movement Disorders Society . Rolling through September 18, the event brings together thousands of movement disorder specialists – including top neurologists and Parkinson’s disease (PD) researchers – to share insights that can move the field forward. Selected as a Poster Tour accolade, the Foundation’s PD GENEration Genetic Registry study will be featured multiple times, including a guest plenary presentation by the Principal Investigator, Roy AlcalayMD, MS.

“The recognition of PD GENEration at an international forum is a testament to the impact this study has already had in the field and represents our commitment to bringing improvements to Parkinson’s disease care and research,” said the Associate Vice President of Clinical Research. Anna Naito, PhD, from the Parkinson Foundation. “We are confident that PD GENEration’s contributions to the global research community will bring us closer to scientific breakthroughs. Through PD GENEration, we have developed international collaborations with experts from across the field, enabling us to accelerate the field of research and treatment globally.

Parkinson’s Foundation poster presentations will include:

Curation of Parkinson’s disease genes and gene variants by an authoritative panel of experts

With advances in the field of Parkinson’s disease toward precision medicine, the Foundation has established an expert panel for PD genetics under ClinGen – an FDA-recognized global resource that uses criteria at the scale to determine gene-disease relationships. The members of the PD Gene Curation Expert Panel (PD GCEP) bring together 58 experts from several countries representing geneticists, Parkinson’s clinicians, biochemists, genetic counselors and pharmaceutical companies. The PD GCEP aims to inform the FDA and pharmaceutical companies on the prioritization of key disease-related genes.

Closing the Gap: Increasing Access to Genetic Testing and Counseling for Hispanics through Parkinson’s Research

This poster describes the efforts of the PD GENEration Genetic Registry Study and the GEN-EP Latino Study to reach Hispanic populations in the United States, Porto Rico and the Dominican Republic. Preliminary results include a total of 22 Hispanic participants identified as carriers of a well-known pathogenic/probably pathogenic variant of PD, representing 14.5% of all individuals tested. Increasing the diversity of genetic data from diverse populations will help accelerate understanding of the causes and many symptoms associated with PD.

PD GENEration clinical phase: genetic diagnostic yield and clinical characteristics

This study aims to assess the prevalence of genetic forms of PD in North America via PD GENEration. Among the North American PD GENEration cohort, 14.8% of participants carried a genetic variant linked to PD. Widespread genetic testing in North America will help identify previously unsuspected individuals with major PD gene variants and ultimately qualify more people for enrollment in precision medicine clinical trials for PD.

Implementation of team-based outpatient palliative care at Parkinson Foundation Centers of Excellence (COEs): study design

Despite accumulating evidence on the benefits of integrated palliative care (PC) approaches for people with neurological conditions and their families, there are few models on how to implement and spread this model of care. The core intervention is based on a successful team-based CP model developed at three Parkinson Foundation Centers of Excellence in the United States and validated in a multi-site randomized controlled trial. This poster describes the study design and early lessons of an implementation project to make integrated CP a new standard of care at all 33 Centers of Excellence in the United States.

Patient Advisory Committees: A Model for Patient Involvement in Comparative Effectiveness Research in Parkinson’s Disease

To address the lack of comparative effectiveness research (CER) in PD and the need to begin building infrastructure to fill this gap, this pilot project aimed to create a replicable and sustainable model of patient engagement in PD. PD CER in academic research centers through Patient Advice Cards (PAB). This pilot project offers a patient engagement model in academic PD research centers that can facilitate the involvement of people with PD from the community at different stages of the research process, such as when setting priorities. research, protocol design and considerations.

Screening and Treatment for Depression in Parkinson’s Disease in Movement Disorders Centers: A Quality Improvement Initiative

A significant proportion of people with PD who report depressed mood do not receive mental health services or treatment. This study aims to assess the feasibility of routine screening for depression using a 15-question survey of people with PD at six centers of excellence and to identify barriers within the specialist setting for depression. movement. Systematic screening for depression will help improve quality of care and quality of life by educating both clinicians and people with PD.

To view and learn more about the Parkinson Foundation research findings presented at the 2022 MDS International Congress, visit Parkinson.org/Blog. To learn more about the Foundation’s commitment to research, visit Parkinson.org/Research.

About the Parkinson Foundation

The Parkinson Foundation improves the lives of people with Parkinson’s disease by improving care and advancing the search for a cure. In everything we do, we draw on the energy, experience and passion of our global Parkinson’s community. Since 1957, the Parkinson Foundation has invested over $400 million in research and clinical care of Parkinson’s disease. Join us on Parkinson.org, Facebook, TwitterInstagram or call (800) 4PD-INFO (473-4636).

About Parkinson’s disease

Affecting approximately one million Americans and 10 million worldwide, Parkinson’s disease is the second most common neurodegenerative disease after Alzheimer’s disease and the 14th leading cause of death in the United States. It is associated with progressive loss of motor control (eg, tremors or tremors at rest and lack of facial expression), as well as non-motor symptoms (eg, depression and anxiety). Parkinson’s disease is incurable and 60,000 new cases are diagnosed each year in the United States alone.

MEDIA CONTACT:
Marissa Cruz
Parkinson Foundation
[email protected]
305-537-9926
parkinson.org

SOURCE Parkinson Foundation



Source link

]]>
CareDx Shows Global Leadership at The Transplantation Society’s 29th International Congress | Company https://congresips.com/caredx-shows-global-leadership-at-the-transplantation-societys-29th-international-congress-company/ Mon, 12 Sep 2022 11:03:00 +0000 https://congresips.com/caredx-shows-global-leadership-at-the-transplantation-societys-29th-international-congress-company/ BRISBANE, Calif.–(BUSINESS WIRE)–Sept. 12, 2022– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ is focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – announced today its prominent participation in the 29th International Congress of The Transplantation Society (TTS 2022) will take place September 10-14 in […]]]>

BRISBANE, Calif.–(BUSINESS WIRE)–Sept. 12, 2022–

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ is focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – announced today its prominent participation in the 29th International Congress of The Transplantation Society (TTS 2022) will take place September 10-14 in Buenos Aires, Argentina.

Transplant physicians will present data from over 25 abstracts demonstrating the value of AlloSure® donor-derived cell-free DNA (dd-cfDNA) and AlloSeq cDNA in clinical practice, as well as emerging trends and innovation in transplantation, including artificial intelligence and the potential use of CareDx Molecular Testing Services for monitoring xenotransplantation.

“As a leader in transplantation innovation, CareDx is excited to expand its global presence with data from over 25 abstracts presented at this internationally acclaimed TTS Congress,” said Reg Seeto. , CEO and President of CareDx. “We also look forward to sharing information on the next wave of innovation focused on the latest AiKidney™ and AiCAV™ developments.”

Dr Alexandre Loupy, Paris Transplant Group, added: “I look forward to attending the meeting and discussing how artificial intelligence is transforming patient care by helping doctors adapt plans based on the patient’s risk profile for rejection and post-transplant complications.

About CareDx – The Transplant Society

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions. for transplant patients and caregivers. CareDx offers testing services, products and digital healthcare solutions throughout the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward-looking statements

This press release contains forward-looking statements relating to CareDx, Inc., including statements regarding the benefits and potential results that may be achieved through CareDx’s prominent participation in the 29th International Congress of the Transplantation Society (the “ TTS Congress”). These forward-looking statements are based on information currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. , including the risks that CareDx does not realize the expected benefits of its participation in the TTS Congress; the risks that the TTS Congress will not take place at the time and place indicated in this press release; the risks that the data presented at the TTS Congress will not match the statements contained in this press release; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the annual report on Form 10-K for the fiscal year ended December 31, 2021 filed by CareDx with the SEC on February 24, 2022, the report quarterly report on Form 10-Q for the quarter ended March 31, 2022 filed by CareDx with the SEC on May 5, 2022, the quarterly report on Form 10-Q for the quarter ended June 30, 2022 filed by CareDx with the SEC on August 4, 2022 and other reports that CareDx has filed with the SEC. Each of these items could cause CareDx’s actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertakes to update or revise these forward-looking statements.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220912005357/en/

CONTACT: CareDx. Inc.

Media Relations

Anna Czene

(818)731-2203

aczene@caredx.comInvestor Relations

Ian Coney

(415) 722-4563

investor@CareDx.com

KEYWORD: CALIFORNIA BRAZIL SOUTH AMERICA LATIN AMERICA NORTH AMERICA EUROPE ARGENTINA UNITED STATES COLOMBIA

KEYWORD INDUSTRY: HEALTH SURGERY GENETIC HEALTH TECHNOLOGY GENERAL HEALTH PHARMACEUTICALS BIOTECHNOLOGY

SOURCE: CareDx, Inc.

Copyright BusinessWire 2022.

PUBLISHED: 09/12/2022 07:01 / DISK: 09/12/2022 07:03

http://www.businesswire.com/news/home/20220912005357/en

Copyright BusinessWire 2022.


Source link

]]>
Inhibikase Therapeutics to present at the International Congress on Parkinson’s Disease and Movement Disorders https://congresips.com/inhibikase-therapeutics-to-present-at-the-international-congress-on-parkinsons-disease-and-movement-disorders/ Thu, 08 Sep 2022 12:30:00 +0000 https://congresips.com/inhibikase-therapeutics-to-present-at-the-international-congress-on-parkinsons-disease-and-movement-disorders/ BOSTON and ATLANTE, September 8, 2022 /PRNewswire/ — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor treatments to modify the course of Parkinson’s disease, related disorders Parkinson’s and other Abelson tyrosine kinase diseases, today announced that Milton Werner, Ph.D., President and CEO of Inhibikase, will present at the International […]]]>

BOSTON and ATLANTE, September 8, 2022 /PRNewswire/ — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor treatments to modify the course of Parkinson’s disease, related disorders Parkinson’s and other Abelson tyrosine kinase diseases, today announced that Milton Werner, Ph.D., President and CEO of Inhibikase, will present at the International Congress on Parkinson’s Disease and Movement Disorders. The congress is held at Madrid, Spain and almost between September 15-18, 2022.

Inhibikase Therapeutics, Inc. logo (PRNewsphoto/Inhibikase Therapeutics, Inc.)

Presentation details:

Title of abstract: IkT-148009 as a potential disease-modifying therapy in PD
Abstract number: 789
Session: GPT 6, Parkinson’s disease: clinical trials
Presentation date and time: September 16, 2022, 1:00 p.m. – 3:00 p.m. CEST / 7:00 a.m. – 09:00. is
Location: France Gallery, Madrid Marriott Auditorium Hotel and Conference Center

About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing treatments for Parkinson’s disease and related disorders. Inhibikase’s multi-therapeutic pipeline focuses primarily on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease internally and externally. of the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline targets disorders of the brain and gastrointestinal tract related to Parkinson’s disease, orphan indications related to Parkinson’s disease such as multiple system atrophy and drug delivery technologies for kinase inhibitors such as as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate that the company says will provide a better patient experience with fewer dosage-related side effects. The company’s RAMP™ medicinal chemistry program has identified a number of compounds complementary to IkT-148009 that have potential application to other cognitive and motor brain diseases. Inhibikase is headquartered in Atlanta, Georgia with offices at Boston, MA.

Social Media Disclaimer
Investors and others should note that the Company announces important financial information to investors through its investor relations website, press releases, SEC filings, public conference calls and webcasts. The Company also intends to use TwitterFacebook, LinkedIn, and YouTube as a means of disclosing information about the Company, its services, and other matters and to comply with its disclosure obligations under the FD Regulations.

Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes”, “expects”, “may”, “will”, “should”, “anticipates”, “plans” or similar expressions or the negative form of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Inhibikase’s current expectations and assumptions. These statements are subject to certain risks and uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in the documents Inhibikase’s filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, including under the heading “Risk Factors”. Any forward-looking statements in this release speak only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by applicable securities laws.

contacts:

Company Contact:
Milton H. Wernerdoctorate
President and CEO
678-392-3419
info@inhibikase.com

Investor Relations:
Alex Lobo
SternIR, Inc.
alex.lobo@sternir.com

Quote

Quote

See original content to download multimedia: https://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-present-at-the-international-congress-of-parkinsons-disease-and-movement-disorders -301615899.html

SOURCE Inhibikase Therapeutics, Inc.



Source link

]]>
Royan International Congress underway in Tehran https://congresips.com/royan-international-congress-underway-in-tehran/ Wed, 07 Sep 2022 15:02:05 +0000 https://congresips.com/royan-international-congress-underway-in-tehran/ TEHRAN – The Royan International Twin Congress kicked off in Tehran on Wednesday. The 23rd Congress on Reproductive Biomedicine and the 18th Hybrid Congress on Stem Cell Biology and Technology will run until September 9. A total of 84 speakers, including 49 from 21 foreign countries, will deliver speeches in three programs Congress on Reproduction, […]]]>

TEHRAN – The Royan International Twin Congress kicked off in Tehran on Wednesday.

The 23rd Congress on Reproductive Biomedicine and the 18th Hybrid Congress on Stem Cell Biology and Technology will run until September 9.

A total of 84 speakers, including 49 from 21 foreign countries, will deliver speeches in three programs Congress on Reproduction, Congress on Stem Cells and Symposium on Nursing and Midwifery.

Randy Schakman, 2013 Nobel laureate and professor at the University of California, Berkeley, gave an online talk on the topic of protein and RNA sorting for intercellular transport.

The Royan International Twin Congress has proven to be one of the most successful science gathering experiences in West Asia since 2000.

During these twenty years of active involvement in the sharing and exchange of scientific knowledge and expertise with renowned scientific institutes and scientists, the Royan Congress has contributed to the establishment of numerous shared scientific projects and exchanges. .
Royan is a non-profit public association affiliated with the university center of education, culture and research. Created in 1991, Royan is a research institute in reproductive biomedicine and infertility treatment; and the world leader in the research and treatment of this field.

The institute also acts as a leader in stem cell research and is one of the best clinics for the treatment of infertility. It has 46 scientific members and 186 laboratory technicians.

FB/MG


Source link

]]>
Savara presented data at the European Respiratory Society (ERS) 2022 International Congress | Company https://congresips.com/savara-presented-data-at-the-european-respiratory-society-ers-2022-international-congress-company/ Tue, 06 Sep 2022 20:07:02 +0000 https://congresips.com/savara-presented-data-at-the-european-respiratory-society-ers-2022-international-congress-company/ AUSTIN, Texas–(BUSINESS WIRE)–Sept. 6, 2022– Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, presented three posters at the 2022 ERS International Congress which took place September 4-6 in Barcelona, ​​Spain. Below are summaries of each poster presented: Abstract #2170: “IMPALA: Measures of Efficacy in Patients with Autoimmune Alveolar Pulmonary Proteinosis […]]]>

AUSTIN, Texas–(BUSINESS WIRE)–Sept. 6, 2022–

Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, presented three posters at the 2022 ERS International Congress which took place September 4-6 in Barcelona, ​​Spain.

Below are summaries of each poster presented:

Abstract #2170: “IMPALA: Measures of Efficacy in Patients with Autoimmune Alveolar Pulmonary Proteinosis (aPAP) Who Required Whole Lung Lavage” presented by Y. Inoue, MD, Ph.D.

  • Presenting data from a post hoc analysis of the IMPALA clinical trial evaluating the benefit of continuous daily administration of 300 μg inhaled molgramostim versus placebo in patients with aPAP who required complete lung lavage ( WLL) during the double-blind treatment period. A total of 10 patients experienced WLL during the treatment period (molgramostim: n=4, placebo: n=6)
  • The data demonstrated that patients treated with molgramostim after undergoing WLL had greater improvements in measures of gas exchange parameters, including the alveolar-arterial oxygen difference (A-aDO 2 ) and the capacity lung diffusion for carbon monoxide (DLco) corrected for hemoglobin levels. Additionally, patients reported improved health status, as measured by the St. George’s Respiratory Questionnaire -Total and -Activity, compared to placebo-treated patients.
  • Click here to see the poster

Abstract #1154: “Safety and Tolerability of Inhaled Molgramostim in Autoimmune Alveolar Pulmonary Proteinosis (aPAP)” presented by F. Bonella, MD, Ph.D.

  • Includes safety data from an open-label, uncontrolled extension study of IMPALA (IMPALA-X) in which 60 patients received treatment with inhaled molgramostim 300 μg/day administered intermittently (1 week walking and 1 week rest). This study was terminated prematurely because the IMPALA results did not support this dosing regimen.
  • In IMPALA-X, no new safety signals were observed and the most common treatment-related adverse events after 93.4 patient-years of exposure were mild to moderate cough, nasopharyngitis and infection of the respiratory tracts.
  • Click here to see the poster

Abstract #3136: “IMPALA-2: Choice of DLco as the primary endpoint in autoimmune pulmonary alveolar proteinosis (aPAP)” presented by B. Trapnell, MD

  • Described rationale for using DLco as the primary endpoint in the IMPALA-2 clinical trial, including:
    • In the first IMPALA trial, DLco showed robust improvements in patients with aPAP who were treated with 300 μg continuous daily molgramostim compared to those treated with placebo
    • DLco is a standardized and widely used pulmonary function test directly related to the pathophysiology of aPAP, and predictive of the major clinical event of WLL
  • IMPALA-2 is an ongoing pivotal global Phase 3, randomized, double-blind, placebo-controlled clinical trial evaluating molgramostim 300 μg once daily in patients with aPAP
  • Click here to see the poster

The full content of these posters is available in the Congress online program and on the Articles and Publications page of the Savara corporate website. In addition, the posters should be published in a supplement to the European Respiratory Journals l (ERJ) by the end of November 2022. For more details on the ERS International Congress, please visit https://www.ersnet.org/congress-and-events/congress/.

About aPAP

Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare lung disease that belongs to a family of distinct rare lung diseases collectively known as pulmonary alveolar proteinosis (PAP). aPAP accounts for approximately 90% of all patients with PAP. Although aPAP can affect people of any age, race, or gender, its onset most often occurs in people between the ages of 30 and 40. PAP is characterized by the accumulation of surfactant in the alveoli, or air sacs, of the lungs. Surfactant consists of proteins and lipids and is an important physiological substance that lines the inside of the alveoli to prevent the lungs from collapsing. The root cause of aPAP is an autoimmune response against GM-CSF, a naturally occurring protein in the body. Lung macrophages must be stimulated by GM-CSF to function properly, but in aPAP, GM-CSF is neutralized by antibodies against GM-CSF, rendering macrophages unable to perform their tasks, including including removal of surfactant from the alveoli. In aPAP, the feeling of having difficulty breathing is the most common symptom. People with aPAP may also experience chronic cough, fatigue, sputum production, reduced ability to exercise, and bouts of fever due to underlying lung infections. There are currently no approved pharmaceutical treatment options for aPAP.

About Savara

Savara is a clinical-stage biopharmaceutical company specializing in rare respiratory diseases. Our flagship program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is administered via an experimental eFlow® nebulizer system (PARI Pharma GmbH). Our leadership team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs and effectively advancing product candidates through approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharmaLinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220906005655/en/

CONTACT: Savara Inc. IR and PR

Anne Erickson

Senior Vice President, Chief of Staff

anne.erickson@savarapharma.com

(512) 851-1366

KEYWORD: TEXAS EUROPE SPAIN UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CLINICAL TRIALS

SOURCE: Savara Inc.

Copyright BusinessWire 2022.

PUBLISHED: 06/09/2022 16:05 / DISK: 06/09/2022 16:07

http://www.businesswire.com/news/home/20220906005655/en

Copyright BusinessWire 2022.



Source link

]]>